GSA Capital Partners LLP Makes New $446,000 Investment in CareDx, Inc. $CDNA

GSA Capital Partners LLP purchased a new position in shares of CareDx, Inc. (NASDAQ:CDNA) during the 3rd quarter, HoldingsChannel reports. The firm purchased 30,670 shares of the company’s stock, valued at approximately $446,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Cetera Trust Company N.A boosted its holdings in CareDx by 11.2% in the second quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock worth $238,000 after purchasing an additional 1,225 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of CareDx by 5.9% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 22,509 shares of the company’s stock worth $440,000 after buying an additional 1,264 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of CareDx by 4.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock worth $542,000 after acquiring an additional 1,280 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of CareDx by 12.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 11,885 shares of the company’s stock valued at $232,000 after acquiring an additional 1,293 shares during the last quarter. Finally, Swiss National Bank increased its holdings in shares of CareDx by 2.0% during the 2nd quarter. Swiss National Bank now owns 100,600 shares of the company’s stock valued at $1,966,000 after acquiring an additional 2,000 shares during the last quarter.

Insider Activity at CareDx

In related news, CEO John Walter Hanna, Jr. sold 19,280 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total value of $407,964.80. Following the completion of the transaction, the chief executive officer directly owned 597,405 shares in the company, valued at approximately $12,641,089.80. This represents a 3.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 29,636 shares of company stock valued at $625,949 in the last three months. Corporate insiders own 4.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CDNA shares. Weiss Ratings restated a “hold (c-)” rating on shares of CareDx in a report on Monday, December 29th. Zacks Research raised shares of CareDx from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 18th. Craig Hallum cut shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective for the company. in a research note on Tuesday, January 6th. Wells Fargo & Company upped their price objective on shares of CareDx from $14.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Finally, Wall Street Zen downgraded shares of CareDx from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $26.67.

CareDx Stock Performance

NASDAQ CDNA opened at $19.25 on Wednesday. CareDx, Inc. has a twelve month low of $10.96 and a twelve month high of $22.95. The stock has a market cap of $990.03 million, a PE ratio of 16.18 and a beta of 2.51. The firm has a 50-day simple moving average of $19.68 and a 200 day simple moving average of $16.74.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.12). CareDx had a net margin of 19.65% and a return on equity of 20.15%. The firm had revenue of $108.39 million during the quarter, compared to analyst estimates of $102.76 million. During the same period last year, the company earned $0.18 EPS. The company’s revenue was up 25.2% on a year-over-year basis. Research analysts forecast that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

More CareDx News

Here are the key news stories impacting CareDx this week:

• Positive Sentiment: Revenue beat and robust top-line growth: Q4 revenue of $108.39M topped consensus (~$102.8M) and rose ~25% year-over-year — a sign demand remains strong for CareDx’s transplant diagnostics and services. CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say
• Positive Sentiment: FY‑2026 revenue guidance came in slightly above Street expectations (range ~$420M–$444M vs. consensus ~$417.5M), giving investors a clearer growth runway and partially offsetting the EPS shortfall. Press Release / Slide Deck
• Neutral Sentiment: Internal leadership change: COO Keith Kennedy will also assume CFO responsibilities — an operational continuity move but one that raises questions about long‑term finance leadership and succession. CareDx Announces Appointment of Keith Kennedy as COO and CFO
• Negative Sentiment: EPS missed meaningfully: GAAP EPS was $0.12 versus consensus ~$0.24, and EPS declined from $0.18 year‑ago — investors often punish earnings misses even when revenue beats, especially for profitability trajectory. CareDx (CDNA) Q4 Earnings Miss Estimates
• Negative Sentiment: Street profitability expectations remain cautious: some analysts now model negative full‑year EPS (consensus commentary showed materially lower EPS expectations for the fiscal year), which may keep valuation pressure despite revenue strength. MarketBeat CDNA Overview

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.